AbbVie’s Setback Gives BMS Commanding Lead in ... - BioSpace
1 day ago · That momentum took a hit last week when AbbVie’s muscarinic candidate emraclidine failed a pair of highly watched mid-stage trials. The announcement also positioned BMS as the clear winner of last year’s schizophrenia sweepstakes. In December 2023, BMS acquired Karuna Therapeutics and its lead asset KarXT (now Cobenfy) for $14 billion just ...
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
1 day ago · ABBV. AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer. The ...
AbbVie News Center - News
6 days ago · AbbVie News Center - News. Latest news. November 11, 2024. AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia. November 07, 2024. Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day. October 31, 2024.
AbbVie's closely watched schizophrenia drug fails two studies
An $8.7 billion "mistake" is likely to weigh on investor sentiment for some time, said Piper Sandler analyst Christopher Raymond, referring to AbbVie's 2023 deal for Cerevel Therapeutics to gain ...
AbbVie raises 2024 profit forecast on strong sales of key drugs …
Oct 30, 2024 · AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings,...
AbbVie Inc. (ABBV) Latest Stock News & Headlines - Yahoo Finance
Get the latest AbbVie Inc. (ABBV) stock news and headlines to help you in your trading and investing decisions.
AbbVie banks on Alzheimer's therapy with $1.4 billion buy of Aliada
Oct 28 (Reuters) - U.S. drugmaker AbbVie (ABBV.N) said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental Alzheimer's treatment still in the early...
AbbVie to Acquire ImmunoGen, including its Flagship Cancer ... - News
Nov 30, 2023 · The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
AbbVie to Acquire Cerevel Therapeutics in Transformative ... - News
Dec 6, 2023 · AbbVie will acquire all outstanding Cerevel common stock for $45.00 per share in cash. The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by Cerevel shareholders.
AbbVie to acquire Cerevel Therapeutics for $8.7 billion - CNBC
Dec 6, 2023 · Key Points. AbbVie said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion. AbbVie will pay $45 per share for Cerevel and expects to complete the acquisition...
- Some results have been removed